Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Teijin beats sales forecasts in quarter, stock rises sharply

Teijin reported fourth-quarter 2025 sales of ¥213.31 billion, beating expectations by 4.82%. Despite a negative earnings per share of -¥150.52, the share price climbed 9.22% to ¥1,711.5. The healthcare segment showed strong growth while the materials business lagged; management is pushing a strategic shift toward customer‑centric solutions. For fiscal 2025, total sales fell to ¥873.2 billion, and Teijin still expects profitability challenges but sees opportunities from restructuring and a focus on Healthcare and Electronics & Energy. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Teijin has already paid €0.13 in dividends. The last payout was in May.

Financials

In the last quarter, Teijin had revenue of €1.22bn and net profit of €41.65m

(EUR)	September 2026	YoY
Revenue	1.22bn	1.86%
Gross profit	346.61m	598.54%
Net profit	41.65m	113.37%
EBITDA	36.23m	116.38%

Fundamentals

Metric	Value
Market capitalization	€1.98bn
Number of shares	193.07m
52-week high/low	€10.67 - €7.07
Dividend yield	2.68%
Dividends TTM	€0.27
Next dividend	€0.14
Beta	0.32
P/E ratio	18.01
PEG ratio	-0.02
P/B ratio	0.83
P/S ratio	0.40

Company profile

Teijin Limited engages in the fibers, films and sheets, composites, healthcare, and IT businesses worldwide. It offers aramid fibers and polyethylene materials; carbon fibers, composite materials, and oxidized PAN fibers; polycarbonate sheets and films; high-density polyethylene porous films and materials; and microporous films. The company also provides PC resins, polyphenylene sulfide resins, molded parts, and additives; lightweight glass and carbon fiber reinforced composites for automotive applications; and polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. In addition, it offers pharmaceuticals for bone and joint, respiratory, cardiovascular and metabolic, and other diseases; home oxygen therapy, non-invasive positive pressure ventilation, rehabilitation, and sleep disordered breathing related devices, as well as sonic accelerated fracture healing system and community-based integrated care system; and orthopedic implantable devices, and functional food ingredients. Further, the company provides Recopic, a radio-frequency identification technology for inventory management. Additionally, it develops and implements engineering solutions for various issues, such as environmental pollution, energy supply stability, and aging-related workforce population decline. Teijin Limited was incorporated in 1918 and is headquartered in Tokyo, Japan.